CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 92-99

  Mikulska, Małgorzata ^a   Raiola, Anna Maria ^a   Bruzzi, Paolo ^a   Varaldo, Riccardo ^a   Annunziata, Silvana ^a   Lamparelli, Teresa ^a   Frassoni, Francesco ^a   Tedone, Elisabetta ^a   Galano, Barbara ^a   Bacigalupo, Andrea ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Alternative donor; Cord blood transplant; Cytomegalovirus; Late CMV infection; Matched unrelated transplant; Serostatus

Indexed keywords

ADOLESCENT; ADULT; AGED; ALTERNATIVE DONOR; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMORPHONUCLEAR CELL; RECIPIENT; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FETAL BLOOD; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84855468000     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.015     Document Type: Article

References (25)

1. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
2. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
3. Ljungman P., Hakki M., Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010, 24:319-337.
4. Konoplev S., Champlin R.E., Giralt S., et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001, 27:877-881.
5. Cohen Y.C., Scaradavou A., Stevens C.E., et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant 2011, 46:70-76.
6. Escalon M.P., Komanduri K.V. Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Curr Opin Oncol 2010, 22:122-129.
7. Seggewiss R., Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010, 115:3861-3868.
8. Mikulska M., Del Bono V., Raiola A.M., et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009, 15:47-53.
9. Frassoni F., Gualandi F., Podesta M., et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
10. Bacigalupo A., Bregante S., Tedone E., et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996, 62:376-380.
11. Bacigalupo A., Tedone E., Isaza A., et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995, 16:155-161.
12. Bregante S., Bertilson S., Tedone E., et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000, 26:23-29.
13. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
14. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
15. Ozdemir E., Saliba R.M., Champlin R.E., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40:125-136.
16. Albano M.S., Taylor P., Pass R.F., et al. Umbilical cord blood transplantation and cytomegalovirus: Posttransplantation infection and donor screening. Blood 2006, 108:4275-4282.
17. Beck J.C., Wagner J.E., DeFor T.E., et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:215-222.
18. Takami A., Mochizuki K., Asakura H., Yamazaki H., Okumura H., Nakao S. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica 2005, 90:1290-1292.
19. Walker C.M., van Burik J.A., De For T.E., Weisdorf D.J. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007, 13:1106-1115.
20. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
21. Komanduri K.V., St John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
22. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
23. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
24. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 363:2091-2101.
25. Junghanss C., Storb R., Maris M.B., et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003, 123:662-670.